

Information about proposed Board of Directors Annual General Meeting 2019

Proposal for re-election of the current members of the board of directors:

Håkan Björklund

Chairman

Born 1956. Ph.D. from Karolinska Institutet in Stockholm. Board member and chairman since 2016.

Other appointments: Industry Executive at Avista Capital Partners.

Previous appointments: CEO and President of Nycomed. Håkan has served as a Member of the Board of Director of several international life science companies including Alere, Coloplast, Danisco and Lundbeck. Between 2001 and 2007, Håkan Björklund also served as member of the Board of Directors for Biovitrum.

Shares: 15,800

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Håkan Björklund is proposed for re-election both as member of the board of directors and as chairman of the board.

David Allsop

Born 1963. BSc Hons Chemistry from Coventry University, UK. Board member since 2018.

Other appointments: Director and sole employee in U-R-NOT Ltd., through which Mr. Allsop offers advisory services to the pharma industry.

Previous appointments: More than 30 years' of experience from research as well as marketing within the pharmaceuticals and health care industries. International experience from the pharmaceutical and biotechnology industry and a commercial and general management background. Until January 2018, Head of International in Amicus Therapeutics Ltd. A number of senior positions in Biogen 1998–2015.

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Annette Clancy

Born 1954. BSc Hons Pharmacology from Bath University UK. Board member since 2014.

Other appointments: Non-executive Chairman of the Board of Enyo SA and Lysogene SA. Member of the Board of Directors of Obseva SA.

Previous appointments: Senior European Advisor to the Biopharmaceutical Team of Frazier Healthcare. Chair of the Board of Directors of Genable Therapeutics. Non-Executive Board Director of Silence

Therapeutics plc. and Clavis Pharma. Head of Transaction and Alliance Management at GlaxoSmithKline (GSK).

Shares: 3,414

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Matthew Gantz

Born 1965. BA Princeton University and MBA from Harvard Business School. Board member since 2012.

Other appointments: CEO of OxThera AB. Member of the board of Pennsylvania Life Sciences Association and Marine Corps Scholarship Foundation.

Previous appointments: Executive Vice President of BTG. Founder and CEO of Acureon Pharmaceuticals, CEO of Hydrabiosciences Inc., Vice President Europe for Chiron's Biopharmaceutical Division and General Manager for PathoGenesis Europe, as well as a variety of US sales and marketing roles at Abbott Laboratories Diagnostic Division

Shares: 0

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Lennart Johansson

Born 1955. MBA from Stockholm School of Economics. Board member since 2010

Other appointments: Member of the management team and Senior Advisor at Patricia Industries (division of Investor AB). Chairman of the board of Fastighets AB Tingshuset 13, board member of Vectura Fastigheter AB, Hi3G, Chalmers Ventures and Bonesupport AB, and deputy board member of Mölnlycke Health Care.

Previous appointments: Chairman of the Board of Vectura Fastigheter AB, CEO in b-business partners and Emerging Technologies AB. Board member of SAAB AB, IBX Group AB and Gambro Holding AB.

Shares: 20,000

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Helena Saxon

Born 1970. MSc from Stockholm School of Economics. Board member since 2011.

Other appointments: CFO at Investor AB. Member of the Board of Directors of SEB.

Previous appointments: CFO of Hallvarsson & Halvarsson, Vice President at Investor AB and financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Shares: 15,500

Independent in relation to the company and its management but dependent in relation to the company's principal shareholders.

Hans GCP Schikan

Born 1958. Pharmacist, Utrecht University. Board member since 2011.

Other appointments: Chairman of the Board of Directors of Interna, the Netherlands and Complix, Belgium. Member of the Board of Directors of Vicore Pharma, Sweden, Therachon, Switzerland as well as of the Dutch Top Sector Life Sciences & Health, the Netherlands. Advisor to various organisations in Life Sciences & Health.

Previous appointments: CEO of Prosensa, Director of the Supervisory Board of Prosensa. Board member of Hansa Medical, Wilson Therapeutics and Asceneuron. Various senior management positions within former Organon and Genzyme.

Shares: 4,000

Independent in relation to the company and its management and in relation to the company's principal shareholders.

Elisabeth Svanberg

Born 1961. MD and PhD from the University of Gothenburg, Sweden. Associate professor of surgery. Board member since 2018.

Other appointments: Chief Development Officer at Ixaltis SA in France since 2016. Member of the Board of Directors of PledPharma AB.

Previous appointments: Board member of Follicum AB and of the Swedish American Chamber of Commerce New York. Head of the Established Products Group at Janssen Pharmaceuticals 2014–2016. Lead the development of a novel diabetes medicine and served as Head of Medical Affairs for the Intercontinental region at Bristol Myers Squibb (BMS) in the US 2007–2014. Held leading roles in R&D for metabolic diseases at Serono International, Switzerland, 2000–2007.

Shares: 260

Independent in relation to the company and its management and in relation to the company's principal shareholders.